Novavax Shares Drop 9%; U.S. Plans to Secure 3.2M Doses of Covid Vaccine

2
2
Favorite

Novavax Shares Drop 9%; U.S. Plans to Secure 3.2M Doses of Covid Vaccine

Dow Jones2022-07-12

By Kathryn Hardison

Shares of Novavax Inc. declined 9.3% to $69.01 on Monday after it said the U.S. government agreed to secure an initial 3.2 million doses of the company's Covid-19 vaccine if it is cleared by regulators for emergency use.

The U.S. Food and Drug Administration is reviewing Novavax's application for an emergency authorization. If it receives the FDA authorization, plus recommendation from the Centers for Disease Control and Prevention, Novavax said its vaccine would be the first protein-based Covid vaccine in the U.S.

Novavax shares were down 52% for the year.

Write to Kathryn Hardison at kathryn.hardison@wsj.com

$(END)$ Dow Jones Newswires

July 11, 2022 14:29 ET (18:29 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（2）

KC69
·2022-07-12
Always the surprise price movement
Reply
Like
Report
XLMM
·2022-07-12
Hope the approval comes asap!
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2250963154?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-07-12 02:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2250963154","market":"us","top_or_hot":-1,"title":"Novavax Shares Drop 9%; U.S. Plans to Secure 3.2M Doses of Covid Vaccine","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kathryn Hardison \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Novavax Inc. declined 9.3% to $69.01 on Monday after it said the U.S. government agreed to secure an initial 3.2 million doses of the company's Covid-19 vaccine if it is cleared by regulators for emergency use. \n</p>\n<p>\n  The U.S. Food and Drug Administration is reviewing Novavax's application for an emergency authorization. If it receives the FDA authorization, plus recommendation from the Centers for Disease Control and Prevention, Novavax said its vaccine would be the first protein-based Covid vaccine in the U.S. \n</p>\n<p>\n  Novavax shares were down 52% for the year. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kathryn Hardison at kathryn.hardison@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  July 11, 2022 14:29 ET (18:29 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Shares Drop 9%; U.S. Plans to Secure 3.2M Doses of Covid Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Shares Drop 9%; U.S. Plans to Secure 3.2M Doses of Covid Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-07-12 02:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Kathryn Hardison \n\n\n \n\n\n  Shares of Novavax Inc. declined 9.3% to $69.01 on Monday after it said the U.S. government agreed to secure an initial 3.2 million doses of the company's Covid-19 vaccine ...</p>\n\n<a href=\"http://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2250963154","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2250963154","pubTimestamp":1657564140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"By Kathryn Hardison \n\n\n \n\n\n  Shares of Novavax Inc. declined 9.3% to $69.01 on Monday after it said ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","BK4139":"生物科技","NVAX":"诺瓦瓦克斯医药"},"translate_title":"Novavax股价下跌9%；美国计划获得320万剂Covid疫苗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":1},"content_text":"By Kathryn Hardison \n\n\n \n\n\n  Shares of Novavax Inc. declined 9.3% to $69.01 on Monday after it said the U.S. government agreed to secure an initial 3.2 million doses of the company's Covid-19 vaccine if it is cleared by regulators for emergency use. \n\n\n  The U.S. Food and Drug Administration is reviewing Novavax's application for an emergency authorization. If it receives the FDA authorization, plus recommendation from the Centers for Disease Control and Prevention, Novavax said its vaccine would be the first protein-based Covid vaccine in the U.S. \n\n\n  Novavax shares were down 52% for the year. \n\n\n \n\n\n  Write to Kathryn Hardison at kathryn.hardison@wsj.com \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  July 11, 2022 14:29 ET (18:29 GMT)\n\n\n  Copyright (c) 2022 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9071767713,"gmtCreate":1657587003132,"gmtModify":1676536030187,"author":{"id":"4087302404901900","authorId":"4087302404901900","name":"KC69","avatar":"https://static.tigerbbs.com/24bd0655f50ef1da3a0e432d0399825f","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4087302404901900","authorIdStr":"4087302404901900"},"htmlText":"Always the surprise price movement","listText":"Always the surprise price movement","text":"Always the surprise price movement","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9071767713","repostId":2250963154,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9071525816,"gmtCreate":1657573231135,"gmtModify":1676536025331,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://community-static.tradeup.com/news/5fd3a75ea7ccf88aca493e34c270e676","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":1,"crmLevelSwitch":0,"idStr":"4100909250192760","authorIdStr":"4100909250192760"},"htmlText":"Hope the approval comes asap!&nbsp;","listText":"Hope the approval comes asap!&nbsp;","text":"Hope the approval comes asap!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9071525816","repostId":2250963154,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":2,"commentSize":2,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}